Sunday, October 4, 2026

USD/CAD Bearish By 1% In The Last 21 Sessions

ViaNews Editorial Team

September 4, 2024

USD/CAD Bearish By 1% In The Last 21 Sessions

(VIANEWS) - USD/CAD (USDCAD) has been up by 1.67% for the last 21 sessions. At 08:12 EST on Wednesday, 4 September, USD/CAD (USDCAD) is $1.36.

USD/CAD's yearly highs and lows, it's 2.877% up from its 52-week low and 2.776% down from its 52-week high.

Volatility

USD/CAD's last week, last month's, and last quarter's current intraday variation average was a positive 0.15%, a negative 0.11%, and a positive 0.19%, respectively.

USD/CAD's highest amplitude of average volatility was 0.15% (last week), 0.21% (last month), and 0.19% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CAD's Forex is considered to be oversold (<=20).

Previous days news about USD/CAD (USDCAD)

  • Usd/cad extends its recovery near 1.3500 as traders brace for US PMI data. According to FXStreet on Monday, 2 September, "The USD/CAD pair trades on a stronger note near 1.3500 during the early Asian session on Tuesday. "
  • Usd/cad rises to near 1.3550 as traders assess ISM manufacturing PMI. According to FXStreet on Tuesday, 3 September, "This upside of the USD/CAD pair is attributed to the improved US Dollar (USD) amid decreasing odds of an aggressive interest rate cut by the US Federal Reserve rate in September."

More news about USD/CAD (USDCAD).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Citigroup Inc.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com